BIRC5 and endometrial cancer: In our previous work published in Gynecologic Oncology, we also showed that survivin was expressed in 87.5% of endometrial cancer cell lines and that high expression of BIRC5 gene was significantly associated with poor progression-free survival (p = 0.006), and was an independent prognostic factor (HR = 1.97, 95% CI = 1.29–4.5, p = 0.045) (26).